MCK · 8-K · 20260805PR000232

Acquisition / Partnership / Divestiture

MCKESSON CORP · 2026-08-05 · Importance 53 · Surprise 60 · In source text

McKesson sold Apollo Funds an approximately 13% minority interest in Medical-Surgical Solutions for $1.25 billion on June 1, 2026. The transaction generated a $293 million redemption-value adjustment for redeemable noncontrolling interests in the quarter. McKesson also established a $2.25 billion secured Term Loan B facility on June 9, 2026, to support the planned separation, and named the future standalone business Wellverse on August 5, 2026.

Key facts

• On June 1, 2026, McKesson sold an approximately 13% minority interest in its Medical-Surgical Solutions business to Apollo Funds for $1.25 billion. source
• Sale of noncontrolling interest in Medical-Surgical Solutions, net cash received in quarter: $1,238 million. source
• On August 5, 2026, McKesson unveiled Wellverse as the name of the future standalone Medical-Surgical Solutions business. source
• Effective August 1, 2026, Thomas L. Rodgers retired as Executive Vice President, Chief Strategy and Business Development Officer and Ramesh Srinivasan assumed the role of Executive Vice President and Chief Strategy Officer. source
• Schedule note: Transaction-related charge of $293 million (pre-tax and after-tax) within Medical-Surgical Solutions related to remeasurement to redemption value of redeemable noncontrolling interests from Apollo Funds acquisition of ~13% interest. source
• Schedule note: Transaction-related charge of $81 million (pre-tax and after-tax) within Oncology & Multispecialty related to remeasurement of redeemable noncontrolling interests. source
• Schedule note: Transaction-related expenses include pre-tax charges of $68 million ($50 million after-tax) within Medical-Surgical Solutions and Corporate Expenses related to planned separation for three months ended June 30, 2026. source

Impact estimates